Skip to content

Explore the eye movement characteristics of multiple system atrophy by the EyeKnow intelligent eye movement analysis and evaluation system

The relationship between eye movement and multiple system atrophy was explored based on the brain marrow- brain spirit - brain qi-brain's qi collateral- brain's apertures theory combined with multimodal magnetic resonance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000833
Enrollment
Unknown
Registered
2025-04-24
Start date
2025-04-28
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy

Interventions

Group B(health volunteer):no
Group A(MSA volunteer):no

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of multiple system atrophy; (2) Age is over 30 years old and less than 80 years old gender is not limited; (3) Patients with good compliance to take medicine according to doctor's advice; (4) Other clinical researchers who did not participate in the study; (5) Voluntarily participate in this clinical trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Previous diagnosis of Alzheimer's disease and various secondary Parkinson's syndromes; (2) Neurological examination suggests that there is a systemic disease or other clear cause of brain atrophy or dementia; (3) Vertical rapid saccades were significantly slowed or vertical nuclear gaze palsy; (4) Evidence of local cerebral cortex damage such as aphasia heterotopia parietal lobe dysfunction; (5) moderate to severe head trauma hydrocephalus brain surgery or brain tumor history; (6) History of central nervous system infection metabolism and autoimmune diseases; (7) The presence of psychiatric disorders and hallucinations unrelated to the drug; (8) History of cataract glaucoma or other eye diseases; (9) A history of systemic diseases that may cause ocular symptoms affecting eye tracking; (10) Other factors affecting eye movement such as the use of antipsychotic drugs benzodiazepines or antidepressants within 72h; (11) Pregnant women with serious heart liver and kidney diseases who cannot complete the scale and related examinations; (12) claustrophobia; (13) Other conditions that the investigator considers unsuitable for participation in this study; (14) Refusal to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Evaluation of multiple system atrophy symptoms;

Secondary

MeasureTime frame
Assessment of cognitive status;Multimodal magnetic resonance;Evaluation of the severity of fatigue;Eye movement tests;Parkinson symptom evaluation;Evaluation of non-motor symptoms in multiple system;Evaluation of mental and emotional status;Evaluation of TCM syndrome in brain marrow disease;

Countries

China

Contacts

Public ContactCHEN-Zhigang/LI-Xiufang

Dongfang Hospital Beijing University of Chinese Medicine/Beijing University of Chinese Medicine

chenzhigang64@139.com13601275206/18810813170

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026